Loading
HB-200 is a vaccine built from two harmless engineered viruses that teach the immune system to attack the HPV16 proteins inside cervical and throat cancers. It has been tested with pembrolizumab in HPV16-positive head and neck cancer.
HB-200 is Hookipa Pharma's therapeutic vaccine for HPV16-positive cancers, made of two arenavirus vectors, HB-201 (based on lymphocytic choriomeningitis virus) and HB-202 (based on Pichinde virus), that express the same HPV16 E6/E7 fusion antigen. Alternating the two vectors avoids immunity against the vector itself and produced some of the largest antigen-specific T-cell expansions reported for a cancer vaccine.
It was given intravenously with pembrolizumab in phase 1/2 trials in recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma, with response rates in the first-line setting above those expected from pembrolizumab alone. It is named on the recurrent or metastatic head and neck cancer page among the newer immunotherapy approaches for HPV-positive disease.
Two replicating arenavirus vectors (lymphocytic choriomeningitis and Pichinde virus) each carrying a non-oncogenic HPV16 E6/E7 fusion protein, given alternately to raise very high frequencies of E6- and E7-specific killer T cells against HPV16-driven tumours.
1.HB-200 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"HB-200" OR ABSTRACT:"HB-200" OR TITLE:"HB-201" OR ABSTRACT:"HB-201" OR TITLE:"HB-202" OR ABSTRACT:"HB-202" OR TITLE:"Eseba-vec" OR ABSTRACT:"Eseba-vec") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HB-200, not a curated reading list.
Shares Recurrent or metastatic head and neck squamous cell carcinoma and the tag subtype-drugs-wave.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Pembrolizumab.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Pembrolizumab.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Pembrolizumab.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Pembrolizumab.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Pembrolizumab.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Pembrolizumab.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Pembrolizumab.